Hennessy BT - Search Results

1

An integrative genomic and proteomic analysis of PIK3CA, PTEN, and AKT mutations in breast cancer.

Stemke-Hale K, Gonzalez-Angulo AM, Lluch A, Neve RM, Kuo WL, Davies M, Carey M, Hu Z, Guan Y, Sahin A, Symmans WF, Pusztai L, Nolden LK, Horlings H, Berns K, Hung MC, van de Vijver MJ, Valero V, Gray JW, Bernards R, Mills GB, Hennessy BT. Stemke-Hale K, et al. Among authors: hennessy bt. Cancer Res. 2008 Aug 1;68(15):6084-91. doi: 10.1158/0008-5472.CAN-07-6854. Cancer Res. 2008. PMID: 18676830 Free PMC article.

2

Lower dose capecitabine has a more favorable therapeutic index in metastatic breast cancer: retrospective analysis of patients treated at M. D. Anderson Cancer Center and a review of capecitabine toxicity in the literature.

Hennessy BT, Gauthier AM, Michaud LB, Hortobagyi G, Valero V. Hennessy BT, et al. Ann Oncol. 2005 Aug;16(8):1289-96. doi: 10.1093/annonc/mdi253. Epub 2005 May 12. Ann Oncol. 2005. PMID: 15890665 Free article. Review.

3

Neoadjuvant systemic therapy for breast cancer: an overview and review of recent clinical trials.

Hanrahan EO, Hennessy BT, Valero V. Hanrahan EO, et al. Among authors: hennessy bt. Expert Opin Pharmacother. 2005 Aug;6(9):1477-91. doi: 10.1517/14656566.6.9.1477. Expert Opin Pharmacother. 2005. PMID: 16086636 Review.

4

Adjuvant therapy for breast cancer.

Hennessy BT, Pusztai L. Hennessy BT, et al. Minerva Ginecol. 2005 Jun;57(3):305-26. Minerva Ginecol. 2005. PMID: 16166938 Review.

5

Metaplastic sarcomatoid carcinoma of the breast with absent or minimal overt invasive carcinomatous component: a misnomer.

Davis WG, Hennessy B, Babiera G, Hunt K, Valero V, Buchholz TA, Sneige N, Gilcrease MZ. Davis WG, et al. Am J Surg Pathol. 2005 Nov;29(11):1456-63. doi: 10.1097/01.pas.0000176431.96326.49. Am J Surg Pathol. 2005. PMID: 16224212

6

Squamous cell carcinoma of the breast.

Hennessy BT, Krishnamurthy S, Giordano S, Buchholz TA, Kau SW, Duan Z, Valero V, Hortobagyi GN. Hennessy BT, et al. J Clin Oncol. 2005 Nov 1;23(31):7827-35. doi: 10.1200/JCO.2004.00.9589. J Clin Oncol. 2005. PMID: 16258085

7

Exploiting the PI3K/AKT pathway for cancer drug discovery.

Hennessy BT, Smith DL, Ram PT, Lu Y, Mills GB. Hennessy BT, et al. Nat Rev Drug Discov. 2005 Dec;4(12):988-1004. doi: 10.1038/nrd1902. Nat Rev Drug Discov. 2005. PMID: 16341064 Review.

8

Individualization of neoadjuvant therapy for breast cancer according to molecular tumor characteristics.

Hennessy BT, Gonzalez-Angulo AM, Hortobagyi GN. Hennessy BT, et al. Nat Clin Pract Oncol. 2005 Dec;2(12):598-9. doi: 10.1038/ncponc0375. Nat Clin Pract Oncol. 2005. PMID: 16341096 No abstract available.

9

Outcome after pathologic complete eradication of cytologically proven breast cancer axillary node metastases following primary chemotherapy.

Hennessy BT, Hortobagyi GN, Rouzier R, Kuerer H, Sneige N, Buzdar AU, Kau SW, Fornage B, Sahin A, Broglio K, Singletary SE, Valero V. Hennessy BT, et al. J Clin Oncol. 2005 Dec 20;23(36):9304-11. doi: 10.1200/JCO.2005.02.5023. J Clin Oncol. 2005. PMID: 16361629

10

Identification of remodeling and spacing factor 1 (rsf-1, HBXAP) at chromosome 11q13 as a putative oncogene in ovarian cancer.

Hennessy BT, Nanjundan M, Cheng KW, Nolden L, Mills GB. Hennessy BT, et al. Eur J Hum Genet. 2006 Apr;14(4):381-3. doi: 10.1038/sj.ejhg.5201570. Eur J Hum Genet. 2006. PMID: 16418735 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

215 results

Search Page

Filters